Skip to main content

Table 2 Baseline characteristics and demographics of the population received adjuvant treatment. Data are expressed as numbers (percentage) or mean (range)

From: Adjuvant Chemotherapy with Chinese Herbal Medicine Formulas Versus Placebo in Patients with Lung Adenocarcinoma after Radical Surgery: a Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial

 Adjuvant Chemo + CHMFAdjuvant Chemo + PlaceboP-value
(n = 114)(n = 115)
Gender, n (%)  0.596
 Male57 (50%)61 (53%) 
 Female57 (50%)54 (47%) 
Age59.4 ± 7.459.6 ± 7.50.861
ECOG PS, n (%)  0.99
 02 (1.8%)2 (1.7%) 
 1111 (97.4%)112 (97.4%) 
 21 (0.8%)1 (0.9%) 
Smoking history, n (%)  0.224
 Smoked40 (35.1%)50 (43.5%) 
 Never smoke74 (64.9%)65 (56.5%) 
Resection procedure, n (%)  0.333
 Lobectomy108 (94.7%)112 (97.4%) 
 Sublobectomy6 (5.3%)3 (2.6%) 
Video-assaciated, n (%)  0.689
 Yes64 (56.1%)68 (59.1%) 
 No50 (43.9%)47 (40.9%) 
pTNM stage, n (%)  0.998
 Ib55 (48.2%)56 (48.7%) 
 II22 (19.3%)22 (19.1%) 
 III37 (32.5%)37 (32.2%) 
Chemo regimens, n (%)  0.688
 NP48 (42.1%)45 (39.1%) 
 NC66 (57.9%)70 (60.9%) 
TCM syndrome, n (%)  0.862
 Qi deficiency55 (56.1%)58 (50.4%) 
 Yin deficiency10 (8.8%)8 (7.0%) 
 Qi-Yin deficiency49 (35.1%)49 (42.6%) 
  1. Abbreviations: Chemo, chemotherapy; CHMF Chinese herbal medicine formula, ECOG PS Eastern Cooperative Oncology Group Performance Status, NP Vinorelbine plus cisplatin, NC Vinorelbine plus Carboplatin